# A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

> **NCT01730248** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 63 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** INC424
- **DRUG:** BKM120

## Key facts

- **NCT ID:** NCT01730248
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12-18
- **Primary completion:** 2017-09-28
- **Final completion:** 2017-09-28
- **Target enrollment:** 63 (ACTUAL)
- **Why stopped:** Decision by Sponsor to to terminate the study early.
- **Last updated:** 2020-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01730248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01730248, "A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01730248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*